• 1. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Application of 1,1-Dibromo-3,3-difluoroacetone (CAS: 1309602-53-6) in Chemical Biology and Pharmaceutical Research

1,1-Dibromo-3,3-difluoroacetone (CAS: 1309602-53-6) has emerged as a versatile building block in synthetic chemistry and pharmaceutical research due to its unique reactivity profile. Recent studies highlight its potential in the synthesis of fluorinated heterocycles, which are increasingly important in drug discovery. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in constructing difluoromethylated pyrimidines, a scaffold with enhanced metabolic stability for kinase inhibitors.

In the context of prodrug development, researchers at MIT reported (2024, ACS Chemical Biology) that 1,1-dibromo-3,3-difluoroacetone serves as a key precursor for masked aldehyde prodrugs. The compound's ability to undergo controlled hydrolysis under physiological conditions enables targeted drug release, particularly in tumor microenvironments where esterase activity is elevated. This addresses a critical challenge in chemotherapy delivery systems.

Structural studies using X-ray crystallography (Nature Communications, 2023) revealed that derivatives of 1309602-53-6 exhibit unique halogen bonding patterns that can be exploited for protein-ligand interactions. Specifically, the dibromo moiety shows preferential binding to sulfur-containing amino acid residues, suggesting applications in covalent inhibitor design for cysteine proteases.

From a safety perspective, recent toxicological assessments (Regulatory Toxicology and Pharmacology, 2024) indicate that proper handling protocols are essential when working with 1,1-dibromo-3,3-difluoroacetone. While the compound shows low acute toxicity (LD50 > 2000 mg/kg in rodents), its vapor pressure requires adequate ventilation in laboratory settings. These findings have important implications for industrial-scale applications.

The pharmaceutical industry has shown growing interest in this compound, with three patent applications filed in Q1 2024 alone (USPTO database) covering its use in: 1) Antibody-drug conjugate linkers, 2) Fluorinated contrast agents for MRI, and 3) PROTAC degraders targeting bromodomain proteins. This intellectual property activity suggests significant commercial potential for derivatives of 1309602-53-6.

Looking ahead, the combination of computational chemistry and high-throughput screening (as reported in Chemical Science, 2024) is accelerating the discovery of new applications for this bifunctional reagent. Molecular dynamics simulations predict particularly promising results for its use in covalent inhibitor development against SARS-CoV-2 main protease, with in vitro validation studies currently underway at multiple research institutions.

• 431-67-4(1,1-Dibromo-3,3,3-trifluoroacetone)
• 883233-85-0(3-bromo-1,1-difluoropropan-2-one)
• 431-91-4(1,1,1-tribromo-3,3,3-trifluoroacetone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)